Raptor Pharmaceutical Corp. (NASDAQ:RPTP) shares were down 7.1% on Monday . The stock traded as low as $6.36 and last traded at $6.40, with a volume of 558,464 shares traded. The stock had previously closed at $6.89.

Several research analysts have weighed in on RPTP shares. Leerink Swann reissued an “outperform” rating and issued a $11.00 price objective on shares of Raptor Pharmaceutical Corp. in a research report on Tuesday, April 12th. Oppenheimer Holdings Inc. reissued a “market perform” rating on shares of Raptor Pharmaceutical Corp. in a research report on Monday, April 11th. Cowen and Company reissued a “buy” rating and issued a $8.00 price objective on shares of Raptor Pharmaceutical Corp. in a research report on Sunday, April 17th. Citigroup Inc. cut Raptor Pharmaceutical Corp. from a “buy” rating to a “neutral” rating and boosted their price objective for the stock from $6.00 to $8.00 in a research report on Monday. Finally, Wedbush reissued a “neutral” rating and issued a $4.00 price objective on shares of Raptor Pharmaceutical Corp. in a research report on Friday, May 6th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $7.17.

The stock’s 50 day moving average price is $5.77 and its 200-day moving average price is $4.86. The company’s market cap is $553.64 million.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last issued its earnings results on Thursday, August 4th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.02. During the same quarter in the prior year, the business posted ($0.17) earnings per share. The business had revenue of $32.05 million for the quarter, compared to analysts’ expectations of $28.52 million. The business’s revenue for the quarter was up 37.4% on a year-over-year basis. Equities research analysts anticipate that Raptor Pharmaceutical Corp. will post ($0.95) earnings per share for the current year.

A hedge fund recently raised its stake in Raptor Pharmaceutical Corp. stock. Cornerstone Capital Management Holdings LLC. raised its stake in shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) by 319.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 251,803 shares of the company’s stock after buying an additional 191,703 shares during the period. Cornerstone Capital Management Holdings LLC. owned 0.30% of Raptor Pharmaceutical Corp. worth $1,310,000 at the end of the most recent quarter.

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.